Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes

Abstract 1. The metabolism of dydrogesterone was investigated in human liver cytosol (HLC) and human liver microsomes (HLM). Enzymes involved in dydrogesterone metabolism were identified and their relative contributions were estimated. 2. Dydrogesterone clearance was clearly higher in HLC compared to HLM. The major active metabolite 20α-dihydrodydrogesterone (20α-DHD) was only produced in HLC. 3. The formation of 20α-DHD by cytosolic aldo-keto reductase 1C (AKR1C) was confirmed with isoenzyme-specific AKR inhibitors. 4. Using recombinantly expressed human cytochrome P450 (CYP) isoenzymes, dydrogesterone was shown to be metabolically transformed by CYP3A4 and CYP2C19. 5. A clear contribution of CYP3A4 to microsomal metabolism of dydrogesterone was demonstrated with HLM and isoenzyme-specific CYP inhibitors, and confirmed by a significant correlation between dydrogesterone clearance and CYP3A4 activity. 6. Contribution of CYP2C19 was shown to be clearly less than CYP3A4 and restricted to a small group of human individuals with very high CYP2C19 activity. Therefore, it is expected that CYP2C19 genetic variations will not affect dydrogesterone pharmacokinetics in man. 7. In conclusion, dydrogesterone metabolism in the liver is dominated primarily by cytosolic enzymes (particularly AKR1C) and secondarily by CYP3A4, with the former exclusively responsible for 20α-DHD formation.

[1]  T. Penning,et al.  Role of aldo–keto reductase family 1 (AKR1) enzymes in human steroid metabolism , 2014, Steroids.

[2]  S. Gobec,et al.  Expression of human aldo-keto reductase 1C2 in cell lines of peritoneal endometriosis: Potential implications in metabolism of progesterone and dydrogesterone and inhibition by progestins , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  I. Blair,et al.  Stereospecific reduction of 5β-reduced steroids by human ketosteroid reductases of the AKR (aldo-keto reductase) superfamily: role of AKR1C1-AKR1C4 in the metabolism of testosterone and progesterone via the 5β-reductase pathway. , 2011, The Biochemical journal.

[4]  S. Gobec,et al.  Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. , 2011, Chemico-biological interactions.

[5]  P. Scherpenisse,et al.  Dydrogesterone: Metabolism in man , 1980, European Journal of Drug Metabolism and Pharmacokinetics.

[6]  K. Schweppe.  The place of dydrogesterone in the treatment of endometriosis and adenomyosis. , 2009, Maturitas.

[7]  A. Mueck,et al.  Use of dydrogesterone in hormone replacement therapy. , 2009, Maturitas.

[8]  S. Malik,et al.  Effective post-laparoscopic treatment of endometriosis with dydrogesterone , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[9]  J. Wiebe.  Progesterone metabolites in breast cancer. , 2006, Endocrine-related cancer.

[10]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[11]  R. Riley,et al.  Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[12]  H. Yamazaki,et al.  Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. , 1997, Archives of biochemistry and biophysics.

[13]  W. Miller,et al.  Extraadrenal steroid 21-hydroxylation is not mediated by P450c21. , 1989, The Journal of clinical investigation.

[14]  C. Ashmore.  Stretch-induced growth in chicken wing muscles: effects on hereditary muscular dystrophy. , 1982, The American journal of physiology.

[15]  R. Strickler,et al.  20 alpha-Hydroxysteroid dehydrogenase and 17 beta-estradiol dehydrogenase localize in cytosol of human term placenta. , 1982, The American journal of physiology.